MEI Pharma, Inc. (MEIP) Reports High Response Rate in Pracinostat + Vidaza Phase II in AML
Tweet Send to a Friend
MEI Pharma, Inc. (Nasdaq: MEIP) announced preliminary response data from the first stage of a two-stage, open-label Phase II clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
